Caveolin‐1 protein expression as a prognostic biomarker of gastrointestinal tumours: A systematic review and meta‐analysis

Abstract

AbstractBackgroundGastrointestinal (GI) cancers remain a major threat worldwide, accounting for over 30% of cancer deaths. The identification of novel prognostic biomarkers remains a challenge despite significant advances in the field. The CAV1 gene, encoding the caveolin‐1 protein, remains enigmatic in cancer and carcinogenesis, as it has been proposed to act as both a tumour promoter and a tumour suppressor.MethodsTo analyse the differential role of caveolin‐1 expression in both tumour cells and stroma in relation to prognosis in GI tumours, we performed a systematic review and meta‐analysis according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines; PROSPERO registration number: CRD42022299148.ResultsOur analysis showed that high levels of caveolin‐1 in tumour cells were associated with poor prognosis and inferior overall survival (OS) in oesophageal and pancreatic cancer and hepatocellular carcinoma (HCC), but not in gastric and colorectal cancer. Importantly, our study showed that higher stromal caveolin‐1 expression was associated with significantly longer OS and disease‐free survival in colorectal cancer. Analysis of stromal caveolin‐1 expression in the remaining tumours showed a similar trend, although it did not reach statistical significance.ConclusionsThe data suggest that caveolin‐1 expression in the tumour cells of oesophageal, pancreatic cancer and HCC and in the stroma of colorectal cancer may be an important novel predictive biomarker for the clinical management of these diseases in a curative setting. However, the main conclusion of our analysis is that caveolin‐1 expression should always be assessed separately in stroma and tumour cells.